Review comparing anti-CGRP monoclonal antibody performance in clinical trials versus real-world evidence, showing real-world efficacy often matches or exceeds trial results with good safety profiles.
Works in real life tooAnti-CGRP antibodies perform at least as well in routine clinical practice as in controlled trials — the real-world evidence validates the clinical trial promise
What the researchers found
Real-world evidence for anti-CGRP monoclonal antibodies shows efficacy consistent with or exceeding clinical trial results, with maintained favorable safety profiles in routine clinical practice.
Why it matters
Real-world evidence confirms that the benefits of anti-CGRP drugs seen in carefully controlled trials translate to actual patient care — reassuring for both doctors and patients.
The numbers in context
Drugs: erenumab, fremanezumab, galcanezumab, eptinezumab; Phase III + real-world data; CGRP + PACAP pathways
How the study worked
Narrative review comparing randomized controlled trial data with real-world evidence studies for anti-CGRP monoclonal antibody migraine treatment.
Who was studied
N/A (review of episodic and chronic migraine patients from clinical trials and real-world practice)
What this study cannot tell us
Real-world studies have inherent biases (selection, recall, reporting). Comparison between trial and real-world data is indirect. Long-term real-world data still accumulating.
How to read the evidence
Moderate evidence: review comparing RCTs (high evidence) with real-world data (lower evidence but higher external validity).
When this study was published
Published 2021. Real-world anti-CGRP evidence continues to grow with expanding clinical use.
The bigger picture
The strong real-world performance of anti-CGRP drugs validates the CGRP hypothesis of migraine and supports expanded access to these treatments.
Questions still open
- Why might real-world efficacy exceed trial results?
- Are there specific patient populations that respond best in real-world settings?
- Does long-term real-world use reveal safety concerns not seen in trials?
Common questions
Do anti-CGRP drugs work as well in real life as in studies?
Are there any new safety concerns from real-world use?
Read the original research
Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?
Pharmaceuticals (Basel, Switzerland), 14(7)
Citation
Mavridis, Theodoros; Deligianni, Christina I; Karagiorgis, Georgios; Daponte, Ariadne; Breza, Marianthi; Mitsikostas, Dimos D. (2021). Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?. Pharmaceuticals (Basel, Switzerland), 14(7). https://doi.org/10.3390/ph14070700